Development and validation of a machine learning model for central compartmental lymph node metastasis in solitary papillary thyroid microcarcinoma via ultrasound imaging features and clinical parameters

基于超声成像特征和临床参数,构建并验证用于孤立性乳头状甲状腺微癌中央区淋巴结转移的机器学习模型

阅读:1

Abstract

BACKGROUND: Papillary thyroid microcarcinoma (PTMC) is the most common malignant subtype of thyroid cancer. Preoperative assessment of the risk of central compartment lymph node metastasis (CCLNM) can provide scientific support for personalized treatment decisions prior to microwave ablation of thyroid nodules. The objective of this study was to develop a predictive model for CCLNM in patients with solitary PTMC on the basis of a combination of ultrasound radiomics and clinical parameters. METHODS: We retrospectively analyzed data from 480 patients diagnosed with PTMC via postoperative pathological examination. The patients were randomly divided into a training set (n = 336) and a validation set (n = 144) at a 7:3 ratio. The cohort was stratified into a metastasis group and a nonmetastasis group on the basis of postoperative pathological results. Ultrasound radiomic features were extracted from routine thyroid ultrasound images, and multiple feature selection methods were applied to construct radiomic models for each group. Independent risk factors, along with radiomics features identified through multivariate logistic regression analysis, were subsequently refined through additional feature selection techniques to develop combined predictive models. The performance of each model was then evaluated. RESULTS: The combined model, which incorporates age, the presence of Hashimoto's thyroiditis (HT), and radiomics features selected via an optimal feature selection approach (percentage-based), exhibited superior predictive efficacy, with AUC values of 0.767 (95% CI: 0.716-0.818) in the training set and 0.729 (95% CI: 0.648-0.810) in the validation set. CONCLUSION: A machine learning-based model combining ultrasound radiomics and clinical variables shows promise for the preoperative risk stratification of CCLNM in patients with PTMC. However, further validation in larger, more diverse cohorts is needed before clinical application. CLINICAL TRIAL NUMBER: Not applicable.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。